- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.19: 4 residues within 4Å:- Chain A: N.122, T.124, N.125, V.127
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain A: E.132, N.165
- Chain G: I.468
- Chain H: Y.108
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: N.280, E.281, N.282
Ligand excluded by PLIPNAG.22: 6 residues within 4Å:- Chain A: N.616, T.618, E.619, Q.644, T.645
- Chain D: I.834
Ligand excluded by PLIPNAG.23: 5 residues within 4Å:- Chain A: F.338, G.339, N.343, L.368, S.371
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain A: N.331, Q.580
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: N.709, G.1131
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain A: C.15, N.17
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain A: Y.28, T.29, N.61
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain D: N.122, T.124, N.125, V.127
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain A: I.468
- Chain B: Y.108
- Chain D: E.132, N.165
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain D: N.280, E.281, N.282
Ligand excluded by PLIPNAG.31: 6 residues within 4Å:- Chain D: N.616, T.618, E.619, Q.644, T.645
- Chain G: I.834
Ligand excluded by PLIPNAG.32: 5 residues within 4Å:- Chain D: F.338, G.339, N.343, L.368, S.371
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain D: N.331, Q.580
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain D: N.709, G.1131
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain D: C.15, N.17
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain D: Y.28, T.29, N.61
Ligand excluded by PLIPNAG.37: 4 residues within 4Å:- Chain G: N.122, T.124, N.125, V.127
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain D: I.468
- Chain E: Y.108
- Chain G: E.132, N.165
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain G: N.280, E.281, N.282
Ligand excluded by PLIPNAG.40: 6 residues within 4Å:- Chain A: I.834
- Chain G: N.616, T.618, E.619, Q.644, T.645
Ligand excluded by PLIPNAG.41: 5 residues within 4Å:- Chain G: F.338, G.339, N.343, L.368, S.371
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain G: N.331, Q.580
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain G: N.709, G.1131
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain G: C.15, N.17
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain G: Y.28, T.29, N.61
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- de Taeye, S.W. et al., Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy. Plant Biotechnol J (2025)
- Release Date
- 2025-01-29
- Peptides
- Spike glycoprotein: ADG
COVA2-15 heavy chain variable region: BEH
COVA2-15 kappa chain variable region: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
HE
DH
EC
LF
FI
G
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- de Taeye, S.W. et al., Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy. Plant Biotechnol J (2025)
- Release Date
- 2025-01-29
- Peptides
- Spike glycoprotein: ADG
COVA2-15 heavy chain variable region: BEH
COVA2-15 kappa chain variable region: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
HE
DH
EC
LF
FI
G